Notice: Automattic\Jetpack\Sync\Functions was called incorrectly. Not all plugins have loaded yet but we requested the class Automattic\Jetpack\Sync\Functions Please see Debugging in WordPress for more information. (This message was added in version 9999999-dev.) in /opt/bitnami/apps/wordpress/htdocs/wp-includes/functions.php on line 4778
Harm Minimisation on the agenda at APP - APP Conference 2020

Australian Pharmacy Professional Conference & Trade Exhibition

Harm Minimisation on the agenda at APP

In 2018, the Therapeutic Goods Administration (TGA) approved two products to be used for opioid addiction.

Buvidal® (buprenorphine depot injection) is approved as the maintenance treatment of opioid dependence; while Nyoxid® (naloxone nasal spray) is approved as an antidote for opioid overdose.

The availability of these products on the Australian market will be a positive step to optimise treatment options and access to those who use opioids.

These two products will now be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) for the Pharmaceutical Benefits Scheme (PBS) in March 2019.

Don’t miss the chance to hear from the most recognisable and influential people in the sector, with the opportunity to ask questions and learn more about the treatment of addiction in this country.

Other topics include:

  • Hepatitis C Treatment – how things have changed
  • Caught in the drug court
  • Legal and lethal

When: 9:00am to 12:30pm, Sunday 10 March 2019
Where: Meeting Room 9, GCCEC

Download the flyer below for more details.